Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ledipasvir/sofosbuvir

- PMLiVE

Two new hepatitis C therapies fast-tracked in Europe

EMA speeds review process for Gilead and AbbVie treatments

- PMLiVE

Gilead’s Hepatitis B therapy Vemlidy granted EU approval

Treatment shows similar efficacy to the firm's Viread at one-tenth of dosage

- PMLiVE

Gilead files hepatitis C salvage regimen in US

Seeks FDA approval for combination of Epclusa and voxilaprevir

- PMLiVE

Another late-stage setback tarnishes Gilead’s R&D lustre

Myelofibrosis drug candidate fails to best Incyte/Novartis’ Jakafi in phase III trials

- PMLiVE

Gilead’s hepatitis B virus treatment set for European approval

CHMP also recommends diabetes drugs from Sanofi and Novo Nordisk

- PMLiVE

Gilead chalks up trial success for new NASH drug

Phase II selonsertib data encouraging for liver disease with no approved therapies

- PMLiVE

SMC approves Opdivo combo as first-line skin cancer treatment

Also backs Gilead’s Epclusa, Baxalta’s Oncaspar, AZ’s Lynparza and Amicus’ Galafold

- PMLiVE

Torrid times at Gilead lead to calls for a major M&A deal

HIV portfolio sales down almost 10% to $7.5bn despite strong $533m start for Epclusa

- PMLiVE

Could Gilead face early Sovaldi generics in Europe?

EU patent protection for the hepatitis C virus drug will end in 2024

Gilead Sciences

Gilead’s ulcerative colitis antibody flunks trial

Halts trial early as preliminary data shows no evidence of efficacy

- PMLiVE

Global pharma market forecast to reach $1.12tr by 2022

Annual growth of 6.3 per cent expected and biologics are set to occupy a stronger position

- PMLiVE

Merck & Co gets EU green light for hep C drug Zepatier

Will enter a market currently dominated by Gilead's Harvoni and Sovaldi

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links